Methods for in vitro—in vivo efficacy determination
View Patent ↗The invention provides methods for determining and evaluating the in vitro-in vivo activity relationship of the efficacy of families of compounds for infectious diseases such as tuberculosis . The validity of the methods can be confirmed by evaluation of the compounds in animal models, for example, in murine models of tuberculosis . Examples of families of antibacterial compounds that can be evaluated for in vivo efficacy using the in vitro methods described herein include benzimidazoles, pyridopyrazines, pteridines, diphenyl ethers, beta-lactams, PBP inhibitors, and compounds that are non-ribonucleic acid and protein synthesis inhibitors. The methods can be used to evaluate classes of small molecule compounds and inhibitors that may be effective against any bacterial pathogen. The methods aid the identification of compounds, such as various benzimidazoles, with modes of action having activity against clinical isolates, as well as non-replicating persistent bacilli, which can therefore enhance current clinical therapeutic regimens.
1. A method for detecting bactericidal antibacterial compounds, the method comprising:
(a) measuring the minimal inhibitory concentration (MIC) in vitro of a pool of antibacterial compounds with respect to an infectious bacteria selected from the group consisting of replicating or non-replicating bacilli and M. tuberculosis;
(b) selecting one or more compounds from the pool of compounds, wherein the one or more selected compounds have a lower MIC than the MIC of 50% of the pool of compounds;
(c) measuring the drug concentration response curve (kill-curve) of the selected compounds with respect to the infectious bacteria;
(d) identifying compounds from step (c) that display a zonal kill-curve, which zonal kill-curve is characterized by a narrow range of concentrations of effective bactericidal activity wherein the narrow range is about 0.5×MIC to about 4×MIC, thereby indicating bacteriostatic activity above the MIC;
(e) identifying compounds from step (c) that display a sigmoidal kill-curve, which sigmoidal kill-curve is characterized by an inhibitory threshold as the concentration of the compound increases, thereby indicating bactericidal activity at the inhibitory threshold;
f) eliminating the compounds identified in step (d) from the compounds measured in step (c); and
(g) measuring the in vitro metabolic stability of one or more remaining compounds in step (f);
wherein one or more metabolically stable bactericidal compounds are detected in the pool of the one or more remaining antibacterial compounds of step (g), wherein a metabolically stable compound:
(i) has less than 2% hydrolysis rate in human plasma and less than 15% hydrolysis rate in mouse plasma, each over a four hour period; or
(ii) has less than 15% conversion rate in the presence of human liver microsomes and less than 20% conversion rate in the present of mouse liver microsomes.
2. The method of claim 1 further comprising selecting one or more metabolically stable bactericidal compounds detected in step (g) for in vivo profiling in M. tuberculosis animal models of infection.
3. The method of claim 1 wherein one or more compounds that display a zonal kill-curve display a compound-tolerant phenotype by eliciting a stress/adaptive response when assessing the drug concentration response curve of the one or more compounds.
4. The method of claim 1 wherein the pool of compounds is evaluated for activity against clinical strains of M. tuberculosis.
5. The method of claim 1 wherein the pool of compounds is evaluated for activity against non-replicating bacilli.
6. The method of claim 4 wherein M. tuberculosis is multidrug resistant (MDR) M. tuberculosis.
7. The method of claim 1 wherein the one or more selected compounds having MIC lower than the MIC of 50% of the pool of compounds are identified, thereby forming a first subset of compounds, and the efficacy of the first subset of compounds is measured in an animal model of infection.
8. The method of claim 7 wherein the animal model is a murine model of tuberculosis.
9. The method of claim 1 wherein one or more of the compounds in the pool of compounds kill M. tuberculosis cells or inhibit the growth of M. tuberculosis cells with an MIC 50 of less than about 15 μg/mL.
10. The method of claim 1 wherein the pool of compounds comprises 2,5,6-trisubstituted benzimidazoles, 2,5,7-trisubstituted benzimidazoles, or a combination thereof.
11. The method of claim 1 wherein the pool of compounds comprises 2,5,6-trisubstituted benzimidazoles and the 2,5,6-trisubstituted benzimidazoles comprise a compound illustrated in one of FIGS. 5-6, 11, and 14 , or comprises one or more of SB-P1G10, SB-P3G2, SB-P8B2, SB-P17-A38 and SB-P17-A42:
12. The method of claim 1 wherein the one or more selected compounds having MIC lower than the MIC of 50% of the pool of compounds are identified, forming a first subset of compounds, and one or more compounds of the first subset are evaluated in a long-term murine model of tuberculosis.
13. The method of claim 1 wherein the one or more selected compounds having MIC lower than the MIC of 50% of the pool of compounds are evaluated in PK/PD studies.
14. The method of claim 1 wherein the one or more of the selected compounds having MIC lower than the MIC of 50% of the pool of compounds are not antagonistic with a second antibacterial drug.
15. The method of claim 1 wherein the one or more of the selected compounds having MIC lower than the MIC of 50% of the pool of compounds are not antagonistic or are synergistic with a second antibacterial drug.
16. The method of claim 14 wherein the second antibacterial drug is isoniazid, bedaquiline, pyrazinamide, rifampin, ethambutol, or metronidazole.